Clinical Trial Update: Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating rituximab plus the ESHAP chemotherapy regimen in relapsed or refractory diffuse large B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CISPLATIN (cisplatin)
• CYTARABINE (CYTARABINE)
• Etoposide (Etoposide)
• METHYLPREDNISOLONE (methylprednisolone)
• Rituximab (rituximab)

Snippet

Sponsor: Fudan University | Conditions: Lymphoma | Phase 2 | Status: COMPLETED